MASHINIi

BriaCell Therapeutics Corp..

BCTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

BriaCell Therapeutics Corp. is a biotechnology company focused on developing targeted immunotherapies to fight cancer. Their primary focus is on developing novel immunotherapies that activate the immune system to recognize and eliminate cancer cells. The company's lead product candidate is Bria-IMT™...Show More

Ethical Profile

Mixed.

BriaCell Therapeutics Corp. focuses on developing cancer immunotherapies, with its lead candidate, Bria-IMT, in a Phase 3 trial for metastatic breast cancer, showing potential tumor reduction. Their personalized Bria-OTS platform has reportedly achieved sustained complete resolution of lung metastasis in a patient, with no treatment-limited toxicities observed. The company has received FDA Fast Track designation for Bria-IMT and an NCI grant for Bria-OTS research, alongside an FDA Expanded Access Policy for patients. While these initiatives highlight a strong commitment to health innovation, information regarding price accessibility, broader workforce pay equity, environmental impact, and ethical sourcing practices remains largely unavailable, contributing to a mixed overall ethical profile.

Value Scores

Better Health for All30
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-40
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

30

BriaCell Therapeutics Corp. is entirely focused on developing immunotherapies to fight cancer, including metastatic breast cancer, prostate cancer, lung cancer, and melanoma.

1
Its lead product candidates, Bria-IMT™ and Bria-OTS™, are in clinical trials (Phase 1/2, Phase 3).
2
Bria-IMT™ has received FDA Fast Track designation and FDA authorization for an Expanded Access Policy.
3
Clinical data indicates potential tumor reduction, increased survival compared to literature, and in one case, complete resolution of lung metastasis sustained for 6 months with Bria-OTS™.
4
The company's products have been reported as safe in Phase I/IIa trials, with no treatment-limited toxicities observed for Bria-OTS™ in a patient case study.
5
The company has received non-dilutive research grants from the National Cancer Institute (NCI) to advance its immunotherapy research, and is expanding its R&D team.
6

Fair Money & Economic Opportunity

0

No evidence available to assess BriaCell Therapeutics Corp. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No specific, quantitative evidence was found in the provided articles to assess BriaCell Therapeutics Corp. against the defined KPIs for Fair Pay & Worker Respect. Information regarding living wage coverage, CEO median pay ratio (due to lack of median employee compensation data), collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage for the general workforce was not available.

1

Fair Trade & Ethical Sourcing

0

No data on BCTX.US's fair trade and ethical sourcing practices was found in the provided article.

1
The article focuses on the company's cancer immunotherapy development, clinical trials, and awards, with no information relevant to supply chain ethics, certifications, audits, or supplier diversity.
2

Honest & Fair Business

0

No evidence available to assess BriaCell Therapeutics Corp. on Honest & Fair Business.

Kind to Animals

-40

The FDA waived the requirement for animal toxicology and pharmacokinetic studies for Bria-PROS+™, indicating that non-animal assays are accepted for regulatory submissions for this product.

1
However, animal models were used in studies for sCD80 (Bria-IMT™).
2
The company's policy prohibits discretionary testing, but legal mandates still override alternatives, as evidenced by the use of animal models for Bria-IMT™ and the waiver for Bria-PROS+™ for specific studies. The company has an AI-driven collaboration with Receptor.AI to design isoform-selective kinase inhibitors, which is a form of animal-free R&D.
3
BriaCell engages with the FDA, as evidenced by a Pre-IND meeting and the authorization of an Expanded Access Policy, publicly endorsing specific animal welfare reforms by accepting non-animal data where possible.
4

No War, No Weapons

0

BriaCell Therapeutics Corp. is described as a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer care.

1
The provided articles consistently indicate that the company's activities center around research, development, and clinical testing of pharmaceutical products for cancer treatment. There is no evidence in the articles to suggest any involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, or any other defense-related activities. Therefore, all KPIs are scored as N/A (0), as they are not applicable to the company's core business operations.

Planet-Friendly Business

0

No specific, quantifiable evidence was found in the provided articles for BCTX.US regarding any of the Planet-Friendly Business KPIs. The articles discuss general sustainable laboratory practices and industry-wide trends, or provide data for other companies like AstraZeneca

1
or Harvard University
2
, but do not offer any concrete data points directly attributable to BCTX.US.

Respect for Cultures & Communities

0

No evidence available to assess BriaCell Therapeutics Corp. on Respect for Cultures & Communities.

Safe & Smart Tech

0

The provided articles focus exclusively on BriaCell Therapeutics Corp.'s clinical trial results for its cancer immunotherapies and FDA Fast Track designations.

1
No information or specific data points related to data protection, cybersecurity, AI ethics, privacy practices, or digital rights advocacy were found across any of the articles.
2
Therefore, no KPIs under the 'Safe & Smart Tech' value can be scored based on the evidence provided.

Zero Waste & Sustainable Products

0

No specific, concrete data points related to waste management, product sustainability, or zero-waste metrics were found in the provided articles.

1
All articles either explicitly state a lack of sustainability data or show null values for relevant key performance indicators.

Own BriaCell Therapeutics Corp.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.